Singh Annapurna
Department of Ophthalmology, 11100 Euclid Avenue, Case Western Reserve University, Cleveland, OH 44106, USA.
Ophthalmol Clin North Am. 2005 Sep;18(3):397-408, vi. doi: 10.1016/j.ohc.2005.05.001.
Prescribing medical treatment for glaucoma requires a complex decision-making process that involves the patient, the severity of the disease, the therapeutic options available, and their potential side effects. Lowering intraocular pressure, a known risk factor for progression, has been the mainstay of glaucoma treatment. Most patients who are first diagnosed with glaucoma in the United States are started on topical medications. As our understanding of the disease changes and newer treatments become available, glaucoma therapies may need to be reassessed and changed if necessary.
开青光眼的药物治疗处方需要一个复杂的决策过程,这涉及患者、疾病的严重程度、可用的治疗选择及其潜在的副作用。降低眼压是疾病进展的已知危险因素,一直是青光眼治疗的主要手段。在美国,大多数首次被诊断为青光眼的患者开始使用局部用药。随着我们对该疾病的认识发生变化以及有了更新的治疗方法,如果有必要,青光眼治疗可能需要重新评估和改变。